Literature DB >> 15330127

Risk factors for hepatitis C virus infection among blood donors in Georgia.

Nickolas Zaller1, Kenrad E Nelson, Malvina Aladashvili, Nino Badridze, Carlos del Rio, Tengiz Tsertsvadze.   

Abstract

BACKGROUND: Growing awareness about the importance of blood safety for controlling the transmission of hepatitis C virus (HCV) has helped to decrease the spread of this virus in many settings. This study was conducted in order to evaluate potential risk factors for HCV infection among blood donors in Georgia.
METHODS: The study population consisted of 553 blood donors in three major Georgian cities: Tbilisi, the capital city and Batumi and Poti, naval port cities. Risk factors were examined using a behavior questionnaire. All blood samples were initially tested using 3rd generation anti-HCV enzyme-linked immunosorbent assays and confirmed using recombinant immunoblot assays and nucleic acid testing.
RESULTS: Forty-three blood donors, 7.8%, were confirmed HCV positive. Significant risk factors included: drug injection ever (OR: 42; 95% CI: 3.2-550.7); history of hepatitis (OR: 25.9; 95% CI: 4.6-145.5); history of a previous surgical procedure (OR: 148.4; 95% CI: 26.9-817.4); blood transfusion (OR: 25.9; 95% CI: 3.2-210.9).
CONCLUSIONS: This study found a very high prevalence of HCV among blood donors in Georgia. The main risk factor for HCV infection in this population of blood donors was previous contact with contaminated blood or blood products. Reliable screening of donors and their blood is critical for controlling the further spread of HCV in Georgia.

Entities:  

Mesh:

Year:  2004        PMID: 15330127     DOI: 10.1023/b:ejep.0000032352.29173.78

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  30 in total

Review 1.  Hepatitis C: an update.

Authors:  D Moradpour; A Cerny; M H Heim; H E Blum
Journal:  Swiss Med Wkly       Date:  2001-06-02       Impact factor: 2.193

2.  Risk factors for hepatitis C virus infection in United States blood donors. NHLBI Retrovirus Epidemiology Donor Study (REDS)

Authors:  E L Murphy; S M Bryzman; S A Glynn; D I Ameti; R A Thomson; A E Williams; C C Nass; H E Ownby; G B Schreiber; F Kong; K R Neal; G J Nemo
Journal:  Hepatology       Date:  2000-03       Impact factor: 17.425

Review 3.  Epidemiology of the hepatitis C virus.

Authors:  F Ebeling
Journal:  Vox Sang       Date:  1998       Impact factor: 2.144

4.  A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States.

Authors:  R Balasekaran; M Bulterys; M M Jamal; P G Quinn; D E Johnston; B Skipper; S Chaturvedi; S Arora
Journal:  Am J Gastroenterol       Date:  1999-05       Impact factor: 10.864

5.  Age-specific seroprevalence of HIV, hepatitis B virus, and hepatitis C virus infection among injection drug users admitted to drug treatment in 6 US cities.

Authors:  Christopher S Murrill; Howard Weeks; Brian C Castrucci; Hillard S Weinstock; Beth P Bell; Catherine Spruill; Marta Gwinn
Journal:  Am J Public Health       Date:  2002-03       Impact factor: 9.308

6.  Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997-1999.

Authors:  L E Thorpe; L J Ouellet; J R Levy; I T Williams; E R Monterroso
Journal:  J Infect Dis       Date:  2000-11-02       Impact factor: 5.226

Review 7.  Hepatitis C: an epidemiological review.

Authors:  M I Memon; M A Memon
Journal:  J Viral Hepat       Date:  2002-03       Impact factor: 3.728

8.  The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.

Authors:  M J Alter; H S Margolis; K Krawczynski; F N Judson; A Mares; W J Alexander; P Y Hu; J K Miller; M A Gerber; R E Sampliner
Journal:  N Engl J Med       Date:  1992-12-31       Impact factor: 91.245

9.  Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection.

Authors:  C Conry-Cantilena; M VanRaden; J Gibble; J Melpolder; A O Shakil; L Viladomiu; L Cheung; A DiBisceglie; J Hoofnagle; J W Shih
Journal:  N Engl J Med       Date:  1996-06-27       Impact factor: 91.245

10.  A case-control study on the risk factors of hepatitis C virus infection among Koreans.

Authors:  Y S Kim; Y O Ahn; D W Kim
Journal:  J Korean Med Sci       Date:  1996-02       Impact factor: 2.153

View more
  9 in total

1.  Prevalence of hepatitis C, HIV, and risk behaviors for blood-borne infections: a population-based survey of the adult population of T'bilisi, Republic of Georgia.

Authors:  Ketevan Stvilia; Tengiz Tsertsvadze; Lali Sharvadze; Malvina Aladashvili; Carlos del Rio; Mark H Kuniholm; Kenrad E Nelson
Journal:  J Urban Health       Date:  2006-03       Impact factor: 3.671

2.  Prevalence of HBV and HCV among blood donors in Kosovo.

Authors:  Hajrullah Fejza; Skender Telaku
Journal:  Virol J       Date:  2009-02-13       Impact factor: 4.099

3.  Not all injection drug users are created equal: heterogeneity of HIV, hepatitis C virus, and hepatitis B virus infection in Georgia.

Authors:  Mark H Kuniholm; Malvina Aladashvili; Carlos Del Rio; Ketavan Stvilia; Nino Gabelia; Rohit A Chitale; Tengiz Tsertsvadze; Kenrad E Nelson
Journal:  Subst Use Misuse       Date:  2008       Impact factor: 2.164

4.  Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients.

Authors:  Mark H Kuniholm; Jennifer Mark; Malvina Aladashvili; N Shubladze; G Khechinashvili; Tengiz Tsertsvadze; Carlos del Rio; Kenrad E Nelson
Journal:  Int J Infect Dis       Date:  2007-07-23       Impact factor: 3.623

5.  Distribution pattern of HCV genotypes & its association with viral load.

Authors:  Anita Chakravarti; Gaurav Dogra; Vikas Verma; Amit Parkash Srivastava
Journal:  Indian J Med Res       Date:  2011-03       Impact factor: 2.375

6.  Launch of a Nationwide Hepatitis C Elimination Program--Georgia, April 2015.

Authors:  Kiren Mitruka; Tengiz Tsertsvadze; Maia Butsashvili; Amiran Gamkrelidze; Paata Sabelashvili; Ekaterine Adamia; Mari Chokheli; Jan Drobeniuc; Liesl Hagan; Aaron M Harris; Tea Jiqia; Ana Kasradze; Stephen Ko; Vakhtang Qerashvili; Lali Sharvadze; Irina Tskhomelidze; Valeri Kvaratskhelia; Juliette Morgan; John W Ward; Francisco Averhoff
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-24       Impact factor: 17.586

7.  Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis.

Authors:  Nino Lomtadze; Lali Kupreishvili; Archil Salakaia; Sergo Vashakidze; Lali Sharvadze; Russell R Kempker; Matthew J Magee; Carlos del Rio; Henry M Blumberg
Journal:  PLoS One       Date:  2013-12-19       Impact factor: 3.240

8.  The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.

Authors:  Tengiz Tsertsvadze; Lali Sharvadze; Nikoloz Chkhartishvili; Lela Dzigua; Marine Karchava; Lana Gatserelia; Akaki Abutidze; Kenrad E Nelson
Journal:  Virol J       Date:  2016-02-03       Impact factor: 4.099

9.  Assessment of hepatitis C risk factors in center of Iran: A case-control study.

Authors:  Faramarz Shahriari-Fard; Sayed Moayed Alavian; Ziba Farajzadegan; Ali Rabiei; Behrooz Ataei; Mehdi Ataie
Journal:  J Res Med Sci       Date:  2018-10-26       Impact factor: 1.852

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.